CD40-targeted vaccine (Oncovir/Strasbourg University)

N/A

Report date: 2025/03/19 11:37:15

Base Information

Drug NameCD40-targeted vaccine (Oncovir/Strasbourg University)
Drug Alias Nameanti-CD40.Env-gp140 vaccine (Oncovir/Strasbourg University)gp140-anti-CD40 antibody fusion protein vaccine (Oncovir/Strasbourg University)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[4] 
Mechanisms of ActionEnvelope glycoprotein gp160 modulatorsTumor necrosis factor receptor superfamily member 5 modulators
TargetsEnvelope glycoprotein gp160Tumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncovir Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncovir IncUniversité de Strasbourg
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A